Regeneron Pharmaceuticals, Inc. REGN

REGN Company Overview

Regeneron Pharmaceuticals, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and commercialization of medicines for serious diseases. The company operates primarily in the biotechnology and biopharmaceutical industries, with therapeutic areas spanning ophthalmology, immunology, oncology, cardiovascular disease, infectious diseases, hematologic conditions, and rare genetic disorders. Regeneron generates revenue through sales of proprietary medicines, collaborative commercialization agreements, and research and development partnerships. Key revenue drivers have included EYLEA for retinal diseases, Dupixent through its collaboration with Sanofi, and oncology products such as Libtayo.

The company was founded in 1988 by Leonard Schleifer and scientists associated with advances in neurobiology and molecular genetics research. Regeneron evolved from an early-stage research biotechnology firm into a large-cap global biopharmaceutical company through sustained investment in antibody technologies, genetics-based drug discovery, and vertically integrated biologics manufacturing. The company is widely recognized for its proprietary VelociSuite technologies, which support rapid antibody discovery and genetic target validation, contributing to its competitive position within the biotechnology sector.